CL2012000821A1 - Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal. - Google Patents

Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal.

Info

Publication number
CL2012000821A1
CL2012000821A1 CL2012000821A CL2012000821A CL2012000821A1 CL 2012000821 A1 CL2012000821 A1 CL 2012000821A1 CL 2012000821 A CL2012000821 A CL 2012000821A CL 2012000821 A CL2012000821 A CL 2012000821A CL 2012000821 A1 CL2012000821 A1 CL 2012000821A1
Authority
CL
Chile
Prior art keywords
prv
immunogenic composition
animal
nucleic acid
prepare
Prior art date
Application number
CL2012000821A
Other languages
English (en)
Inventor
W Ian Lipkin
Gustavo Palacios
Edgar Brun
Ruth Toril Kongtorp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2012000821A1 publication Critical patent/CL2012000821A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)

Abstract

Composición inmunogénica de reoviris de peces (PRV) que comprende ácido nucleico del PRV; polipéptido; anticuerpo que se une a PRV porque neutraliza o reduce la función o actividad del PRV; uso de la composición inmunogénica que sirve para tratar afecciones de infección por PRV en un animal.
CL2012000821A 2009-10-02 2012-04-02 Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal. CL2012000821A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24805809P 2009-10-02 2009-10-02
US32504710P 2010-04-16 2010-04-16
US38059410P 2010-09-07 2010-09-07

Publications (1)

Publication Number Publication Date
CL2012000821A1 true CL2012000821A1 (es) 2012-08-03

Family

ID=43826692

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2012000821A CL2012000821A1 (es) 2009-10-02 2012-04-02 Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal.
CL2012000822A CL2012000822A1 (es) 2009-10-02 2012-04-02 Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; metodo para reducir nivel de proteina viral.
CL2013002907A CL2013002907A1 (es) 2009-10-02 2013-10-10 Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; y uso para reducir los niveles de proteina viral en una celula de un animal (div.sol.n°822-12).
CL2013002933A CL2013002933A1 (es) 2009-10-02 2013-10-11 Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
CL2016000240A CL2016000240A1 (es) 2009-10-02 2016-01-29 Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2012000822A CL2012000822A1 (es) 2009-10-02 2012-04-02 Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; metodo para reducir nivel de proteina viral.
CL2013002907A CL2013002907A1 (es) 2009-10-02 2013-10-10 Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; y uso para reducir los niveles de proteina viral en una celula de un animal (div.sol.n°822-12).
CL2013002933A CL2013002933A1 (es) 2009-10-02 2013-10-11 Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
CL2016000240A CL2016000240A1 (es) 2009-10-02 2016-01-29 Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.

Country Status (8)

Country Link
US (3) US9366667B2 (es)
EP (2) EP2482825B1 (es)
JP (1) JP2013506672A (es)
CN (1) CN102647988A (es)
CA (2) CA2776534A1 (es)
CL (5) CL2012000821A1 (es)
DK (1) DK179132B1 (es)
WO (2) WO2011041789A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions
CA2922621C (en) * 2013-08-30 2023-05-23 Pharmaq As Method for propagating piscine orthoreovirus
IL230970A0 (en) 2014-02-13 2014-09-30 Univ Ramot Tilapia virus vaccines
EP2933341B1 (en) * 2014-04-18 2017-10-04 Schweitzer Biotech Company Ltd. Methods for detecting pathogen in coldwater fish
WO2015185605A1 (en) * 2014-06-03 2015-12-10 Veterinærinstituttet New reovirus infecting rainbow trout
WO2016075277A1 (en) 2014-11-14 2016-05-19 Patogen Analyse As Novel fish virus and method for detection
US10183072B2 (en) 2014-12-15 2019-01-22 Kimron Veterinary Institute Tilapia virus and uses thereof
CA3083873A1 (en) 2017-12-06 2019-06-13 Intervet International B.V. Use of a non-structural protein from prv to protect against heart and skeletal muscle inflammation
WO2020069658A1 (zh) * 2018-10-05 2020-04-09 福又达生物科技股份有限公司 鱼病原体检测方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
NO344967B1 (en) 2019-01-30 2020-08-03 Patogen As Piscine Orthoreovirus Virulence Markers
CN109971890A (zh) * 2019-04-30 2019-07-05 上海海洋大学 Ii型草鱼呼肠孤病毒的微滴式数字pcr检测试剂盒及其专用引物和探针
CN110079507B (zh) * 2019-05-06 2022-05-20 中国海洋大学 抗牙鲆黏膜免疫球蛋白IgT的单克隆抗体及其应用
CN110408637B (zh) * 2019-08-08 2020-12-25 中国水产科学研究院长江水产研究所 一种草鱼出血病酵母口服疫苗及应用
WO2021122507A1 (en) 2019-12-16 2021-06-24 Intervet International B.V. Inactivated piscine orthoreovirus vaccine
NO346211B1 (en) 2020-07-14 2022-04-19 Patogen As Piscine Orthoreovirus Virulence Markers
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
CN112048575A (zh) * 2020-10-26 2020-12-08 深圳市莱孚生物科技有限公司 一种用于鉴定草鱼出血热病毒的引物及探针以及检测方法
CN113527475B (zh) * 2021-06-07 2022-04-29 浙江省农业科学院 一种分泌鸭新型呼肠孤病毒σC蛋白单抗的杂交瘤细胞、单抗及应用
CN114164159B (zh) * 2021-06-21 2023-10-03 湖南师范大学 一种具有防治鱼类杀鲑气和迟缓爱德华氏菌感染的二联疫苗及其制备方法与应用
KR102734012B1 (ko) * 2021-08-19 2024-11-25 성균관대학교산학협력단 바이러스성 출혈성 패혈증 바이러스에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편, 및 이들의 용도
CL2024000227A1 (es) * 2024-01-25 2024-07-12 Univ Santiago Chile Proteína de piscine orthoreovirus; composición de vacuna; y su uso.
CN118853676B (zh) * 2024-09-03 2025-03-07 中国水产科学研究院淡水渔业研究中心 一种草鱼ii型呼肠孤病毒反义rna及其重组载体、试剂盒和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1380651A2 (en) 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JP4323720B2 (ja) 1998-05-08 2009-09-02 インターベツト・インターナシヨナル・ベー・ベー 魚膵臓病ウイルス構造タンパク質およびその使用
US20080256662A1 (en) * 1999-05-10 2008-10-16 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
JP4786093B2 (ja) 1999-08-03 2011-10-05 インターベツト・インターナシヨナル・ベー・ベー 白点症候群ウイルス由来のタンパク質及びその使用
DE60029327T2 (de) 1999-08-07 2007-07-05 Novartis Ag Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DK1094069T4 (da) 1999-10-18 2008-07-21 Intervet Int Bv DNA kodende for strukturelt protein-1 fra infektiös lakseanæmivirus og anvendelser deraf
CA2402718C (en) 2000-03-11 2013-06-25 Novartis Ag Fish vaccine against piscirickettsia salmonis
CA2325088A1 (en) * 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7407784B2 (en) * 2003-01-20 2008-08-05 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. L-amino acid oxidase with cytotoxic activity from Aplysia punctata
WO2005121325A1 (en) * 2004-06-11 2005-12-22 Pharmaq As Heart and skeletal muscle inflammation (hsmi) virus
US7361468B2 (en) * 2004-07-02 2008-04-22 Affymetrix, Inc. Methods for genotyping polymorphisms in humans
JP4911529B2 (ja) 2005-02-22 2012-04-04 日本碍子株式会社 光変調器
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007020983A1 (ja) * 2005-08-18 2007-02-22 Japan Science And Technology Agency オオムギｅｓｔ配列を利用して作製された二倍体コムギ遺伝地図を用いるコムギの育種方法
DK179025B1 (da) * 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
CN101687900A (zh) 2007-03-07 2010-03-31 恩文塔生物制药公司 双链锁核酸组合物
SG191602A1 (en) * 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
JPWO2010024284A1 (ja) * 2008-09-01 2012-01-26 国立大学法人北海道大学 魚類抗ウイルスワクチン、魚類免疫賦活剤、および魚類免疫付与方法
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions

Also Published As

Publication number Publication date
CL2016000240A1 (es) 2016-07-29
US9395356B2 (en) 2016-07-19
CL2013002907A1 (es) 2014-03-21
WO2011041789A1 (en) 2011-04-07
CL2013002933A1 (es) 2014-06-27
DK179132B1 (en) 2017-11-27
EP2482824B1 (en) 2016-11-30
US20130058968A1 (en) 2013-03-07
CL2012000822A1 (es) 2012-07-20
EP2482824A4 (en) 2013-06-19
JP2013506672A (ja) 2013-02-28
CA2776386C (en) 2018-02-27
DK201170227A (en) 2011-05-11
WO2011041790A1 (en) 2011-04-07
EP2482824A1 (en) 2012-08-08
US20160287694A1 (en) 2016-10-06
US20130072542A1 (en) 2013-03-21
US9366667B2 (en) 2016-06-14
EP2482825B1 (en) 2016-11-23
EP2482825A1 (en) 2012-08-08
EP2482825A4 (en) 2013-06-26
CN102647988A (zh) 2012-08-22
CA2776386A1 (en) 2011-04-07
CA2776534A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
PE20150200A1 (es) Formulacion de anticuerpos
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
BR112012012912A2 (pt) anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
BR112014011254A2 (pt) 2-tiopirimidinonas
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR112013005136A8 (pt) Compostos e composições nematicidas, bem como métodos para controlar pragas de nematódeo
ECSP13012520A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
AR091155A1 (es) Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
BR112016009962A2 (pt) superagonistas de ação prolongada de hormônio glicoproteico